Biotechnology

Wednesday Feb 21, 2024 - 2:07 pm

InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients

Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The…

Wednesday Feb 21, 2024 - 1:19 pm

InvestorNewsBreaks – Modular Medical Inc. (NASDAQ: MODD) Announces Pricing of $10M Public Offering

Modular Medical (NASDAQ: MODD), a development-stage insulin delivery technology company seeking to launch the next generation of easy-to-use and affordable insulin pump technology, previously announced the pricing of its underwritten public offering of 9,090,910 shares of its common stock. The offering is led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s chief executive officer, Morgan Frank, a member of the company’s…

Tuesday Feb 20, 2024 - 3:13 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements…

Tuesday Feb 20, 2024 - 10:27 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the capital of the company at its discretion. The offering may…

Tuesday Feb 20, 2024 - 9:45 am

InvestorNewsBreaks — Astiva Health Opens Doors to New LA-Koreatown Activity Center, Marks ‘Testament’ to Empowering Seniors

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, has opened a new facility in Los Angeles. The company is celebrating the Dec. 16, 2023, opening of its Los Angeles-Koreatown Activity Center. The grand-opening ceremony, which marked a milestone for Astiva in its efforts to serve the senior community of Koreatown, included a ribbon cutting by…

Thursday Feb 15, 2024 - 1:43 pm

InvestorNewsBreaks – Datasea Inc. (NASDAQ: DTSS) Collaborates to Bring Unique Platform to New Customers

Datasea (NASDAQ: DTSS) is a Nevada incorporated digital technology corporation engaged in innovative business segments for intelligent acoustics and 5G multimodal communication technology in China. The company has announced that on Feb. 2, 2024, Guozhong Times (Beijing) Technology Ltd., a subsidiary of the Chinese operating company contractually controlled by Datasea, has entered into a cooperation agreement with Hangzhou Chongda Technology Co., Ltd. (“Chongda”) to increase…

Wednesday Feb 14, 2024 - 9:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer's and age-related macular degeneration. Highlights of the report included that the company closed the 2023…

Tuesday Feb 13, 2024 - 12:34 pm

InvestorNewsBreaks – Renovaro Inc. (NASDAQ: RENB) Fusing AI and Biotech to Accelerate Personalized Medicine, GEDiCube, Cyclomics Enter LOI to ‘Change the Field’

Renovaro (NASDAQ: RENB) today announced the completion of its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, marking a new era in healthcare innovation. According to the announcement, the two subsidiaries will be under the…

Tuesday Feb 13, 2024 - 9:39 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q2 2024 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin…

Monday Feb 12, 2024 - 2:52 pm

InvestorNewsBreaks — Astiva Health Marks Pivotal Phase in Transforming Healthcare Delivery

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector in a recent episode of the Bell2Bell Podcast. “The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology. During the interview,…

Friday Feb 09, 2024 - 2:58 pm

InvestorNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the…

Friday Feb 09, 2024 - 11:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles,…

Thursday Feb 08, 2024 - 3:03 pm

InvestorNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering

Revelation Biosciences (NASDAQ: REVB), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, recently announced the closing of its public offering. The offering consisted of 128,470 shares of the company’s common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its…

Wednesday Feb 07, 2024 - 1:01 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Introducing Breakthrough Technology, Potential ‘Game Changer’ for the Cannabinoid Industry

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM). Its subsidiary, AgLAB Inc., has breakthrough mass spectrometry technology in its AgLAB-1000-D2 mass spectrometer, a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials, and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed…

Tuesday Feb 06, 2024 - 2:43 pm

InvestorNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for a patent application related to the use of Lomecel-B(TM) in Aging-related Frailty sufferers receiving vaccines for conditions such as…

Tuesday Feb 06, 2024 - 11:52 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD…

Tuesday Feb 06, 2024 - 11:28 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb.…

Tuesday Feb 06, 2024 - 9:45 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases,…

Monday Feb 05, 2024 - 11:39 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca's Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2…

Monday Feb 05, 2024 - 11:08 am

InvestorNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Announces Upcoming Launch and Expansion of OPKO Health-Branded Storefront

NextPlat (NASDAQ: NXPL, NXPLW), a global e-Commerce provider, is preparing for the launch of its exclusive OPKO Health-branded storefront on Alibaba Group Holding Limited's ("Alibaba")(NYSE: BABA) Tmall Global in China. The move follows the company’s receipt of the initial set of approvals required to operate the store in the country. “We are pleased to reach this strategic milestone with our partners OPKO and Alibaba because…

Friday Feb 02, 2024 - 12:30 pm

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients

Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies,…

Friday Feb 02, 2024 - 10:27 am

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business days and subsequently revert to trading under its historic symbol…

Tuesday Jan 30, 2024 - 12:38 pm

InvestorNewsBreaks — Astiva Health Featured in Bell2Bell Podcast

Astiva Health, which is rapidly making its mark in the Medicare Advantage Prescription Drug (“MAPD”) sector with its commitment to transforming personalized and comprehensive healthcare, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Dr. Tri T. Nguyen, the co-founder and CEO of Astiva Health, joined the program to…

Tuesday Jan 30, 2024 - 12:03 pm

InvestorNewsBreaks – IBN, BioMedWire to Serve as Official Media Partners for BioPharma Nexus Events

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, has announced its media collaboration with BioPharma Nexus for upcoming events in 2024. BioMedWire, a specialized communications platform dedicated to the life sciences sector and a vital component of IBN’s Dynamic Brand Portfolio, will also serve as an official media partner for the events. Renowned for its expertise in life sciences, BioPharma Nexus organizes industry leading…

Tuesday Jan 30, 2024 - 9:48 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Names New Board Member, Reports on Corporate Updates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has appointed Dr. Sanjiv Chopra to its board of directors. According to the announcement. Chopra will be replacing Nitin Kaushal, who resigned from his position. A professor of medicine and former faculty dean for continuing medical education at Harvard Medical School, Dr. Sanjiv…

Tuesday Jan 30, 2024 - 9:42 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and…

Friday Jan 26, 2024 - 2:25 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Pro-Control-1000(TM) Line Poised to Help Manufacturers Improve Profits, Yields

Astrotech (NASDAQ: ASTC ), an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world, continues to expand its technology into new markets. “Astrotech has announced the introduction of its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech is also announcing the creation of its newest wholly…

Friday Jan 26, 2024 - 1:26 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD

PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on…

Thursday Jan 25, 2024 - 2:31 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Results of Special Meeting

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held at 12:00 p.m. ET on Jan. 25, 2024. According to the announcement, all matters put forward before the company’s shareholders for consideration and approval, as set out in Renovaro’s definitive proxy statement dated Jan. 3, 2024, were approved by…

Thursday Jan 25, 2024 - 1:33 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, who is this year’s Louis-Jeantet Prize recipient. A director at the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), Görlich and his colleague Dr. Matthias Dobbelstein, from the University Medical Center Göttingen (“UMG”), lead teams that have collaborated with Scinai in the discovery…

Wednesday Jan 24, 2024 - 3:15 pm

InvestorNewsBreaks – Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the…

Friday Jan 19, 2024 - 9:56 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview…

Tuesday Jan 16, 2024 - 1:37 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Litigation

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today provided an update regarding its litigation with GBB Drink Lab Inc. (“GBB”). In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations…

Tuesday Jan 16, 2024 - 12:22 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as…

Tuesday Jan 16, 2024 - 12:17 pm

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released a message for its shareholders from CEO Mark Dybul. In the message, Dybul provides an update about key developments the company experienced during 2023, including signing a definitive agreement to combine with the European-based, cutting-edge artificial-intelligence (“AI”) company GEDi Cube; GEDi Cube’s partnership…

Friday Jan 12, 2024 - 1:00 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an unmet need in the industry… PaxMedica is on a mission…

Tuesday Jan 09, 2024 - 11:24 am

InvestorNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew…

Monday Jan 08, 2024 - 11:11 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (“ALS”) and multiple sclerosis (“MS”), today reported new CNM-Au8(R) results from the long-term open label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly…

Friday Jan 05, 2024 - 10:44 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.69M Exercise of Outstanding Warrants

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (“I&I”) biological therapeutic products and provision of boutique CDMO services, has closed on its previously announced exercise of certain outstanding warrants. The exercise involved the purchase of up to 2,606,552 American Depositary Shares (“ADSs”), with each share representing 400 ordinary shares. According to the announcement, the shares had exercise prices ranging…

Thursday Jan 04, 2024 - 12:19 pm

InvestorNewsBreaks – Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) Announces Pricing of US$20M Public Offering

Profound Medical (TSX: PRN) (NASDAQ: PROF) recently announced the pricing of its underwritten public offering of 2,666,667 common shares, each at a price to the public of US$7.50, led by health care-focused institutional investors. Of approximately US$20,000,000 in gross proceeds from the offering, the company intends to use net proceeds to fund the continued commercialization of the TULSA-PRO(R) system in the United States, to fund…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions